Abstract
Background The medium-term effects of Coronavirus disease (COVID-19) on multiple organ health, exercise capacity, cognition, quality of life and mental health are poorly understood.
Methods Fifty-eight COVID-19 patients post-hospital discharge and 30 comorbidity-matched controls were prospectively enrolled for multiorgan (brain, lungs, heart, liver and kidneys) magnetic resonance imaging (MRI), spirometry, six-minute walk test, cardiopulmonary exercise test (CPET), quality of life, cognitive and mental health assessments.
Findings At 2-3 months from disease-onset, 64% of patients experienced persistent breathlessness and 55% complained of significant fatigue. On MRI, tissue signal abnormalities were seen in the lungs (60%), heart (26%), liver (10%) and kidneys (29%) of patients. COVID-19 patients also exhibited tissue changes in the thalamus, posterior thalamic radiations and sagittal stratum on brain MRI and demonstrated impaired cognitive performance, specifically in the executive and visuospatial domain relative to controls. Exercise tolerance (maximal oxygen consumption and ventilatory efficiency on CPET) and six-minute walk distance (405±118m vs 517±106m in controls, p<0.0001) were significantly reduced in patients. The extent of extra-pulmonary MRI abnormalities and exercise tolerance correlated with serum markers of ongoing inflammation and severity of acute illness. Patients were more likely to report symptoms of moderate to severe anxiety (35% versus 10%, p=0.012) and depression (39% versus 17%, p=0.036) and a significant impairment in all domains of quality of life compared to controls.
Interpretation A significant proportion of COVID-19 patients discharged from hospital experience ongoing symptoms of breathlessness, fatigue, anxiety, depression and exercise limitation at 2-3 months from disease-onset. Persistent lung and extra-pulmonary organ MRI findings are common. In COVID-19 survivors, chronic inflammation may underlie multiorgan abnormalities and contribute to impaired quality of life.
Funding NIHR Oxford and Oxford Health Biomedical Research Centres, British Heart Foundation Centre for Research Excellence, UKRI, Wellcome Trust, British Heart Foundation.
Competing Interest Statement
EMT is an author of the following patents: Systems and methods for gated mapping of T1 values in abdominal visceral organs (GB2497668B), Multi-parametric magnetic resonance diagnosis and staging of liver disease (GB2498254B), and Processing MR relaxometry data of visceral tissue to obtain a corrected value of relaxometry data based on a normal iron content for the visceral tissue (GB2513474B), all licensed to Perspectum. EMT, MP, AL and SN are shareholders in Perspectum. SN was a board member and consultant to Perspectum until 2019. TO has the following patents pending: Combined angiography and perfusion using radial imaging and arterial spin labeling, and Off-resonance Correction for Pseudo-continuous Arterial Spin Labeling. TO is author patents titled: Estimation of blood flow rates, Fast analysis method for non-invasive imaging of blood flow using vessel-encoded arterial spin labelling and Quantification of blood volume flow rates from dynamic angiography data, both of which are licensed to Siemens Healthineers. MJ receives royalties from Oxford University Innovations for the commercial use of the FSL software. SKP and SN are authors of the patents for calculating T1 (ShMOLLI) in the heart, liver and abdomen: US patent 61/387,591 licensed to Siemens (SKP only), US patent 61/630,508 licensed to Perspectum (SKP and SN), and US patent 61-630,510 licensed to Perspectum (SKP and SN). All other authors do not have conflicts of interest to declare.
Clinical Trial
This study was registered at ClinicalTrials.gov, NCT04510025
Funding Statement
Research funded by the NIHR Oxford and Oxford Health Biomedical Research Centres, British Heart Foundation Centre for Research Excellence, UKRI, Wellcome Trust, British Heart Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved in the United Kingdom by the North West Preston Research Ethics Committee (reference 20/NW/0235).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Individual de-identified participant data can be made available when the trial is complete, or upon requests directed to the corresponding author.
